Akeso (HKSE:09926) Pre-Tax Income : HK$2,125 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Akeso Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Akeso's pretax income for the six months ended in Dec. 2023 was HK$-598 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2,125 Mil. Akeso's pretax margin was -64.40%.

During the past 6 years, Akeso's highest Pretax Margin was 42.92%. The lowest was -5462.15%. And the median was -488.79%.

Akeso Pre-Tax Income Historical Data

The historical data trend for Akeso's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso Pre-Tax Income Chart

Akeso Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-385.52

-1,565.46

-1,540.53

-1,588.21

2,124.69

Akeso Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial						-994.22	-811.03	-815.57	2,723.02	-598.32

Competitive Comparison of Akeso's Pre-Tax Income

For the Biotechnology subindustry, Akeso's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akeso's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akeso's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Akeso's Pre-Tax Income falls into.

Akeso Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Akeso's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	2370.026	+	0	+	-95.145	+	130.961	+	-281.149
	=	2,125

Akeso's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-446.43	+	0	+	-53.132	+	86.447	+	-185.203
	=	-598

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$2,125 Mil.

Akeso (HKSE:09926) Pre-Tax Income Explanation

Akeso's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-598.318	/	929.049
	=	-64.40%

During the past 6 years, Akeso's highest Pretax Margin was 42.92%. The lowest was -5462.15%. And the median was -488.79%.

Akeso Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Akeso's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Akeso (HKSE:09926) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

AKESF:USA 4RY:Germany

Address

6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437

Website

https://www.akesobio.com

Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.

Executives

Xia Yu	2501 Other
Wang Zhongmin Maxwell	2501 Other
Li Baiyong	2501 Other
Green Court Capital Holdings Limited	2201 Interest of corporation controlled by you
Green Court Capital Management Limited	2102 Investment manager
Green Court Management Holdings Llc	2201 Interest of corporation controlled by you
Yao Yulin	2201 Interest of corporation controlled by you
Shenzhen Capital Group Co., Ltd.	2201 Interest of corporation controlled by you
Xia Yu	2501 Other
Shen Zhen Shi Chuang Xin Tou Zi Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Zheng Xun
Zhong Shan Shi Xun Xiang Gu Quan Tou Zi Guan Li Qi Ye You Xian He Huo
Cantrust (far East) Limited	2301 Trustee
Aquae Hyperion Limited	2101 Beneficial owner
Htkf Investments Limited	2101 Beneficial owner

Akeso (HKSE:09926) Headlines

No Headlines